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Objective: Because almost all pulmonary diseases are not caused by one gene,
multiple gene transfection is required for current gene therapy. Adenovirus is an
important gene therapy vector, but a short duration and the inability of repeated
administration remain limitations. The aims of this study were to evaluate whether
adenoviral vector encoding soluble tumor necrosis factor  receptor immunoglob-
ulin and -galactosidase cotransfection prolongs gene expression and facilitates
repeated vector administration to investigate the feasibility of a cotransfection strategy.
Methods: F344 rats received intratracheal administration of 1 109 plaque-forming
units of adenoviral vector encoding -galactosidase or both adenoviral vector
encoding -galactosidase and adenoviral vector encoding soluble tumor necrosis
factor  receptor immunoglobulin. In the expression study -galactosidase gene
expression in the lung was examined by means of enzyme-linked immunosorbent
assay on days 2, 7, 14, 28, and 56 (n  4/day). In the repeated transfection study,
soluble tumor necrosis factor  receptor immunoglobulin and -galactosidase were
readministered once (7 days after the first adenovirus administration) or twice (on
days 7 and 14; n  4/day). A 2-way factorial analysis of variance was used for
statistical analysis.
Results: Soluble tumor necrosis factor  receptor immunoglobulin and -galacto-
sidase cotransfection prolonged the duration of -galactosidase expression. How-
ever, antiadenovirus antibody production was significantly increased in the cotrans-
fection group. In addition, there was no increase in -galactosidase expression after
readministration of soluble tumor necrosis factor  receptor immunoglobulin and
-galactosidase.
Conclusion: Adenoviral vector encoding soluble tumor necrosis factor  receptor
immunoglobulin and -galactosidase cotransfection prolongs -galactosidase ex-
pression but does not increase -galactosidase expression after repeated adminis-
tration. These results suggest that tumor necrosis factor  is one of the most
important factors in regulating the duration of gene expression. The cotransfection
approach is feasible, but the increase of antiadenovirus antibodies might make
repeated cotransfection unfeasible.
Gene therapy with recombinant adenoviral vectors is currentlybeing used in many clinical gene transfer trials for lung diseases,such as cystic fibrosis and lung cancer.1-3 In experimental lungtransplantation our laboratory has demonstrated the beneficialeffects of gene transfer on ischemia-reperfusion injury and acuterejection in a rat lung graft model by using adenovirus vectors,
cationic lipid vectors, and naked plasmid.4-6
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Recombinant adenoviral vectors have an excellent safety
record and lend themselves readily to commercial-scale
manufacturing. They have been used as the gene-transfer
vector in most clinical studies to date and are efficient
vehicles for gene delivery to nondividing epithelial cells in
the airway. Adenoviruses can be produced and purified in
very high titer, permitting highly efficient gene transfer in a
single administration. However, the duration of expression
is limited by the ability of the gene to replicate during cell
division. There is also evidence that the first-generation
adenoviral vectors induce a cellular immune response in the
recipient, leading to selective destruction of infected cells
and subsequent loss of expression within 14 to 21 days of
transfection. In addition, the in vivo administration of ade-
novirus vectors frequently elicits a neutralizing antibody
response, which reduces the efficacy of subsequent treat-
ments. Methods such as immunosuppression will be re-
quired to overcome this barrier and enable repeat delivery of
adenovirus-based gene therapy for the treatment of chronic
disease.7,8 Use of second-generation adenoviruses (deletion
of E1 and E4 regions) and standard immunosuppression
decrease the inflammatory reaction caused by the adenovi-
rus.9 Cassivi and colleagues10,11 demonstrated that immu-
nosuppression attenuates the host immune response after
adenovirus-mediated transfection of rodent lungs and that
transgene expression after adenovirus-mediated retransfec-
tion is increased and prolonged by transplant immunosup-
pression.
Tumor necrosis factor  (TNF-) is the principal medi-
ator of the acute inflammatory response to many infectious
microbes and is responsible for many of the systemic com-
plications of severe infections and other inflammatory con-
ditions. For example, in experimental arthritis models and
patients with rheumatoid arthritis, neutralization of TNF-
with a soluble type I TNF- receptor immunoglobulin (Ig)
G fusion protein alone12,13 or with an adenoviral vector
construct14-16 decreases arthritic inflammation. Ghivizzani
and associates16 used the TNF- receptor IgG fusion protein
rather than the soluble TNF receptor alone because frequent
administration was required, and the effect was short lived
with just the receptor. The effectiveness of TNF- antago-
nists, such as soluble tumor necrosis factor  receptor
immunoglobulin (sTNF-RI-Ig), in ameliorating inflamma-
tion of the liver and lung has also been demonstrated by
Zhang and coworkers.17 On the basis of these studies, we
chose to use sTNF-RI-Ig in our current study.
Almost all disease processes involve not only 1 but 2 or
more genes, and this can become an important problem for
the future use of gene therapy, which currently transfects
only one gene. Multiple-gene transfer, such as cotransfec-
tion, might permit modulation of concurrent biochemical
pathways involved in lung diseases. Our laboratory has
shown a synergistic benefit by using interleukin 10 and
transforming growth factor 1 compared with transfection
of either cytokine alone.18 However, this approach might
increase the quantity of adenovirus transfected and augment
the formation of antibodies to the adenovirus vector. Un-
fortunately, the antiadenovirus antibodies might reduce the
degree and duration of transgene expression. Importantly,
TNF- has a crucial role in immune-mediated clearance of
adenoviral vectors, and adenovirus gene therapy is pro-
longed in TNF- knockout mice.19 Therefore, we hypoth-
esized that use of a cotransfection approach with the adeno-
viral vector encoding soluble type I TNF- receptor IgG
fusion protein might prolong gene expression and permit
repeated transfection.
The aims of this study were to investigate the feasibility
of the cotransfection strategy by (1) evaluating the effect of
sTNF-RI-Ig and -galactosidase (-gal) gene cotransfection
on achieving prolonged -gal expression and (2) examining
the effects of sTNF-RI-Ig and -gal gene cotransfection on
-gal gene expression after their repeated administration.
The present study demonstrated that sTNF-RI-Ig and -gal
cotransfection was feasible and prolonged the duration of
-gal gene expression. However, repeated administration of
sTNF-RI-Ig and -gal did not have any effect on increasing
-gal expression. Therefore, we also examined the produc-
tion of endogenous TNF- in transfected lungs and antia-
denovirus antibodies to investigate the mechanisms of pro-
longing gene expression.
Materials and Methods
Animals
F344 rats (Harlan Sprague Dawley Inc, Indianapolis, Ind) weigh-
ing 250 to 270 g were used in all experiments. All animal proce-
dures were approved by the Animal Studies Committee at Wash-
ington University. Animals received humane care in compliance
with the “Guide for the Care and Use of Laboratory Animals”
prepared by the National Academy of Sciences and published by
the National Institutes of Health (National Institutes of Health
publication No. 85-23, revised 1985).
Adenoviral Vectors
The recombinant adenovirus serotype 5 carrying the Escherichia
coli LacZ gene encoding for -gal is driven by the constitutive
cytomegalovirus promoter (Gene Therapy Center, University of
North Carolina, Chapel Hill, NC).
Adenovirus TNF- receptor Ig (AdsTNF-RI-Ig) encodes a fu-
sion protein consisting of the extracellular domain of the human
55-kd TNF- receptor and the Ch2 through Ch3 domains of a
mouse IgG1 heavy chain.11 AdsTNF-RI-Ig was a gift from Dr Paul
D. Robbins (Department of Molecular Genetics and Biochemistry,
University of Pittsburgh, Pittsburgh, Pa). Purified viral aliquots
were stored at 80°C in 10% glycerol buffered with 10 mmol/L
Tris, 140 mmol/L NaCl, and 1 mmol/L MgCl2. Immediately before
use, these stocks were thawed and diluted in 0.6 mL of sterile
normal saline.
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Experimental Groups
Animals were transfected intratracheally with 1  109 plaque-
forming units (pfu) of adenovirus encoding AdCMVlacZ* alone
(-gal group) or 1  109 pfu of both AdCMVlacZ and AdsTNF-
RI-Ig (cotransfection group).
Experiment 1: Demonstrate in vivo gene delivery and confirm
expression in the lung of the cotransfected genes sTNF-RI-Ig
and -gal. Two days after cotransfection, sTNF-RI-Ig and -gal
gene expression in the lung was evaluated by means of
immunohistochemistry.
Experiment 2: Evaluate the effect of sTNF-RI-Ig and -gal
genecotransfectiononachievingprolonged-galexpression. The
-gal gene expression in the lung was examined by means of
enzyme-linked immunosorbent assay (ELISA) on days 2, 7, 14,
28, and 56 after cotransfection of sTNF-RI-Ig and -gal (n 
4/day). Antiadenovirus antibodies in the serum were measured by
means of ELISA on each day as well.
Experiment 3: Examine the effects of sTNF-RI-Ig and -gal
gene cotransfection on -gal gene expression after their repeated
administration. sTNF-RI-Ig and -gal were readministered once
(7 days after the first adenovirus transfection) or twice (on days 7
and 14). Initial -gal gene expression in the lung was compared
with the expression on day 7, before the retransfection, and on
days 9, 14, and 16, before the second retransfection, by means of
ELISA (n  4 each). -Gal protein expression after readministra-
tion was measured to determine whether repeated gene transfec-
tion was successful.
Immunohistochemistry of -gal and sTNF-RI
Tyramide Signal Amplification Biotin System kits (NEN Life
Science Products, Inc, Boston, Mass) were used for immunohis-
tochemistry. Briefly, lungs were perfused with 20 mL of normal
saline and 20 mL of HistoChoice (Amresco, Solon, Ohio). Spec-
imens were fixed, cut, mounted, deparaffinized, and then treated
with Dako Target Retrieval Solution (Dako, Carpinteria, Calif).
Sections were incubated for 60 minutes with an FcII receptor
blocker (BD PharMingen, San Diego, Calif) and with Super Block
Blocking Buffer (Pierce Chemical Company, Rockford, Ill). A
biotinylated anti-hTNF RI antibody (R&D Systems, Minneapolis,
Minn) was used for 1 hour at room temperature at 1:40 dilution
without amplification, washed in PBS, and then incubated with
streptavidin–horseradish peroxidase for 30 minutes. Next we de-
tected with DAB substrate (Vector Labs, Burlingame, Calif). This
produced a brown color. Then sections were blocked again for 30
minutes with Super Block as before and incubated with B-Gal
(Polysciences, Warrington, Pa) at 1:500 overnight at 4°C. The next
day, sections were incubated with a biotin anti-rabbit IgG Ready-
to-Use (BioGenex, San Ramon, Calif) for 30 minutes and ampli-
fied with the Tyramide Signal Amplification kit. Sections were
incubated with streptavidin–horseradish peroxidase for 30 minutes
and then 15 minutes with biotinyl tyramide, followed by 30 min-
utes with streptavidin–alkaline phosphatase. We detected the B-
Gal with NBT/BCIP (Vector Labs) for the bluish-purple color.
Slides were then counterstained with methyl green, dehydrated,
mounted, and cover slipped. For negative controls, we used normal
lung with both antibodies. We also tested each antibody on a lung
sample with single transfection.
ELISA
Blood samples (3 mL) were collected into ethylenediamine tet-
raacetic acid–containing tubes with pepstatin A (5 g/mL) and
protease inhibitor cocktail (Complete Mini tabs; Boehringer-
Mannheim, Mannheim, Germany). Plasma was obtained by means
of centrifugation at 1000g for 30 minutes, centrifuged at 15,000g
for 15 minutes, and stored at 80°C until ELISA assessment.
Lung protein was extracted by means of homogenization in lysis
solution containing 100 mmol/L potassium phosphate (pH 7.8),
0.2% triton X-100 with pepstatin A (5 g/mL), and protease
inhibitor cocktail (Complete Mini tabs, Boehringer-Mannheim).
The homogenate was centrifuged at 15,000g for 15 minutes after
extraction at room temperature for 15 minutes, and the supernatant
was stored at 80°C until ELISA assessment. The human
sTNF-RI and rat TNF- ELISA kits (R&D Systems) and the -gal
ELISA kit (Boehringer-Mannheim) were used for protein quanti-
fication. The human sTNF-RI is cross-reactive for human, rat, and
mouse.
ELISA for Antiadenovirus Antibody Production
Viable AdCMVlacZ (109 pfu) was added to lung homogenate and
incubated overnight at 4°C, and the plates were washed 3 times.
Serum samples were diluted 1:1000, incubated for 2 hours at room
temperature, and washed. A goat anti-rat IgG was added, and the
plates were washed again and developed with ABTS Substrate
Solution, which contains ABTS (150 mg; 2,2-azino-bis-[3-ethyl-
benzthiazoline-6-sulfonic acid]) and 0.1 mol/L anhydrous citric
acid. The optical density was determined at 405 nm on a micro-
plate reader. Each sample was assayed in duplicate, and the optical
density reading for each sample was averaged. The neutralizing
antibody assay procedure was similar to that reported by Gall and
colleagues.20
Statistical Analysis
Values are reported as means  SEM. A 2-way factorial analysis
of variance was used for statistical analysis when 2 different
groups of samples were compared.
Results
Experiment 1: Demonstrate in vivo gene delivery and
confirm expression in the lung of the cotransfected
genes sTNF-RI-Ig and -gal
Positive immunohistochemical double staining for sTNF-
RI-Ig and -gal was observed in airway epithelial cells of
cotransfected lungs (Figure 1). Lungs transfected with -gal
alone showed only positive staining for -gal and not sTNF-
RI-Ig, whereas lungs flushed with saline alone did not stain
positive for either gene.
Experiment 2: Evaluate the effect of sTNF-RI-Ig and
-gal gene cotransfection on achieving prolonged -gal
expression
Mean sTNF-RI-Ig protein expression in the cotransfection
group was detected on day 2 (44.7  12.0 ng/mg total
*Escherichia coli lacZ gene, which encodes -galactosidase, driven by the
constitutive cytomegalovirus promoter.
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protein), peaked at day 7 (126.0  19.1 ng/mg total pro-
tein), and returned to baseline by day 14 (0.01  0 ng/mg
total protein). The sTNF-RI-Ig protein expression in the
-gal group was undetectable.
The mean peak -gal protein expression on days 2 and 7
was not significantly different between the cotransfection
and -gal groups (P  .84; Figure 2, A). Importantly, -gal
expression in the cotransfection group on days 28 and 56
was significantly higher than that seen in the -gal group (P
 .0007; Figure 2, B).
Antiadenovirus antibody production in the cotransfection
group was significantly higher than that in the -gal group
(P  .0001, Figure 3). Endogenous TNF- levels in the
lungs of the cotransfection group were lower than those in
the -gal group (P  .006).
Experiment 3: Examine the effects of sTNF-RI-Ig and
-gal gene cotransfection on -gal gene expression
after their repeated administration
Repeated cotransfection of sTNF-RI-Ig and -gal did not
increase -gal protein expression in the lung. However,
antiadenovirus antibody production was increased on days 9
and 16 in both the cotransfection and -gal groups. Further-
more, antiadenovirus titers were significantly higher in the
cotransfection group than in the -gal group on day 9 (P 
.0025). The endogenous TNF- level in the lung on days 9
and 16 was not significantly different between the 2 groups
(P  .73).
Discussion
Adenovirus is an important gene therapy vector, but a short
duration of expression and the inability to perform repeated
administration remain important limitations. Another limi-
tation is that if adenoviruses are delivered in vivo, they
infect all tissues, including the germ line, and thus could
affect subsequent generations. A further problem is that the
current generation of adenoviral vectors are immunogenic,
which reduces the duration of gene expression and makes
repeated administration of the same vector impossible.16,21
Our aim was to investigate whether cotransfection could
prolong gene expression and facilitate repeat vector admin-
Figure 1. Immunohistochemistry for -gal (blue) and sTNF-RI-Ig (brown) gene expression in rat lungs. Strong
positive staining was observed in airway epithelial cells in cotransfected lungs. (A, original magnification, 100;
B, original magnification 400.) The nontransfected control specimen is shown in C at 100 magnification.
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istration. In this study we demonstrated that sTNF-RI-Ig
and -gal cotransfection was feasible and prolongs the
duration of -gal gene expression. However, repeated
sTNF-RI-Ig and -gal cotransfection did not have any effect
on increasing -gal expression.
A principal physiologic function of TNF- is to stimu-
late the recruitment of neutrophils and monocytes to sites of
infection and to activate these cells to eradicate microbes. In
inflammation TNF- is produced in large amounts and
causes systemic clinical and pathologic abnormalities. The
effectiveness of TNF- antagonists, such as sTNF-RI-Ig, in
ameliorating inflammation of the lung has been demonstrated
in acute lung injury.17 However, mechanisms of prolonging
expression with TNF- antagonists are less well understood.
Figure 2. Mean -gal protein expression on days 2 and 7 was not significantly different between the cotransfection
(sTNF-RI-Ig and -gal) and -gal groups. In the -gal group -gal protein expression was evident on day 2,
decreased at day 14, and undetectable on day 56. -Gal expression in the cotransfection group was prolonged and
significantly higher for days 14 to 56 versus that in the -gal group.
Figure 3. Antiadenovirus antibody production in the cotransfection group was significantly higher than that in the
-gal group.
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Acute lung injury is characterized by increased proin-
flammatory cytokine levels and massive neutrophil accumu-
lation in the lung. TNF- is one of the primary factors
driving the early inflammatory response. TNF- signaling
through both the p55 and p75 receptors plays an important
role in the clearance of adenoviral vectors and the magni-
tude of the humoral immune response.22 TNF- also leads
to the elimination of adenovirus-infected cells, and sTNF-
RI-Ig is capable of inhibiting these proinflammatory ef-
fects.16,21,23 In the present study sTNF-RI-Ig and -gal
cotransfection prolongs -gal expression. This prolonged
expression might be caused by the anti-inflammatory effects
of sTNF-RI-Ig because it likely inhibits the destruction of
infected cells and the subsequent loss of gene expression.
This anti-inflammatory effect is similar to that seen in
previous studies using TNF- binding protein with and
without adenoviral constructs.12-17
However, the expression of -gal on days 14 to 56 in the
cotransfected group was higher than that in the -gal group,
but it was substantially lower than the expression on days 2
and 7. The amount of expression after day 14, even though
statistically significant, might not be clinically significant or
applicable. We need to conduct further studies to investigate
how we can achieve prolonged and significant expression
for clinical application.
In addition, antiadenovirus antibody production was sig-
nificantly increased in the cotransfection group. This could
be secondary to the fact that the animals in the cotransfec-
tion group received a total of 2  109 pfu of adenovirus
versus only 1  109 pfu in the -gal group or that the
presence of 2 different adenoviral constructs induces an
amplified immune response than that seen when only one
adenoviral construct is used. This result suggests that the
advantage of cotransfection is the ability to prolong gene
expression, but its disadvantage is that the antiadenovirus
antibody production is increased, limiting the ability to
perform successful repeated vector administration. Hence
the antiadenovirus antibody production might be less im-
portant in determining the duration of expression than other
factors, such as TNF-. On the other hand, Suga and asso-
ciates24 have shown that inhibition of interferon , not
TNF-, and antiadenovirus antibody production are related
to rejection of adenoviral vectors. Therefore, we need fur-
ther studies to evaluate which effects are the most impor-
tant. One way to accomplish this is to augment our exper-
imental design and compare -gal expression and antibody
production between groups receiving 1  109 pfu of ade-
novirus encoding -gal and 1  109 pfu of adenovirus
encoding sTNF-RI-Ig and groups receiving 1  109 pfu of
adenovirus encoding -gal and 1  109 pfu of adenovirus
encoding a nontranscribed control gene. In this fashion the
effect of sTNF-RI-Ig presence can be determined, and the
role of increased viral load can be eliminated.
sTNF-RI-Ig and -gal cotransfection was ineffective in
augmenting -gal expression after their repeated cotrans-
fection. Kolb and associates25 showed that the use of topical
corticosteroids improved gene expression after repeated in-
jection of adenovirus vectors but did not prevent production
of neutralizing antiviral antibodies. We hypothesized that
sTNF-RI-Ig would reduce immunogenic responses and
make repeated cotransfection possible. However, cotrans-
fection increases the quantity of adenovirus transfected and
augments the formation of antibodies to the adenovirus
vector. Unfortunately, these antiadenovirus antibodies
might limit the success of repeated administration. We also
speculate that the low expression might be secondary to the
fact that inhibition of the initial nonspecific inflammatory
component of the immune response to adenovirus does not
necessarily inhibit the development of T or B cell–specific
antiadenovirus response, which would lead to low expres-
sion. Therefore, preventing the production of antiadenovirus
antibodies might be as important as reducing immunogenic
responses in allowing successful repeated vector adminis-
tration.
Currently, gene therapy with adenovirus vectors enlists
the synthetic machinery of the patient’s cells to produce a
therapeutic agent.21 In the clinical setting some patients
receive several drugs to modulate concurrent biochemical
pathways of disease. In experimental septic shock models
antagonists of TNF- can prevent mortality, but clinical
trials with anti-TNF- antibodies or with soluble TNF-
receptors have not shown any benefit in patients with sepsis.
This might be because cytokines other than TNF- elicit
similar responses.26,27 Therefore, cotransfection might be
required to regulate concurrent pathways in clinical gene
therapy.
In conclusion, adenovirus encoding soluble TNF- re-
ceptor Ig and -gal cotransfection prolonged the gene ex-
pression of -gal but did not augment its expression after
repeat cotransfection. These results suggest that TNF- is
the one of the most important factors to regulate the dura-
tion of gene expression. On the other hand, cotransfection
increased antiadenovirus antibodies, which might be the
reason repeated administration was ineffective.
We thank Dr Paul D. Robbins (Department of Molecular Ge-
netics and Biochemistry and Orthopedic Surgery, University of
Pittsburgh School of Medicine, Pittsburgh, Pa) for kindly provid-
ing adenovirus encoding TNF-RI-Ig. We also thank Kathleen
Grapperhaus for technical assistance and Mary Ann Kelly and
Dawn Schuessler for secretarial support. Statistical advice was
obtained from Richard B. Schuessler, PhD.
References
1. Marcel T, Grausz JD. The TMC worldwide gene therapy enrollment
report, end 1996. Hum Gene Ther. 1997;8:775-800.
2. Crystal RG. Transfer of genes to humans: early lessons and obstacles
to success. Science. 1995;270:404-10.
General Thoracic Surgery Suda et al
1160 The Journal of Thoracic and Cardiovascular Surgery ● October 2003
G
TS
3. Swisher SG, Roth JA. p53 gene therapy for lung cancer. Curr Oncol
Rep. 2002;4(4):334-40.
4. Suda T, Mora BN, D’Ovidio F, et al. In vivo adenovirus-mediated
endothelial nitric oxide synthase gene transfer ameliorates lung allo-
graft ischemia-reperfusion injury. J Thorac Cardiovasc Surg. 2000;
119:297-304.
5. Yano M, Mora BN, Ritter JM, et al. Ex vivo transfection of trans-
forming growth factor 1 gene to pulmonary artery segments in lung
grafts. J Thorac Cardiovasc Surg. 1999;117:705-13.
6. D’Ovidio F, Yano M, Ritter JH, Mohanakumar T, Patterson GA.
Endobronchial transfection of naked TGF-beta1 cDNA attenuates
acute lung rejection. Ann Thorac Surg. 1999;68:1008-13.
7. Trapnell BC, Gorziglia M. Gene therapy using adenoviral vectors.
Curr Opin Biotechnol. 1994;5:617-25.
8. Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM.
Cellular immunity to viral antigens limits E1-deleted adenoviruses for
gene therapy. Proc Natl Acad Sci U S A. 1994;88:1172-6.
9. Kanaan SA, Kozower BD, Cassivi SD, Patterson GA. Gene therapy for
lung transplantation. In: Albeda SM, editor. Gene therapy in lung
disease. New York: Marcel Dekker; 2002. p. 457-73.
10. Cassivi SD, Liu M, Boehler A, et al. Transplant immunosuppression
increases and prolongs transgene expression following adenoviral-
mediated transfection of rat lungs. J Heart Lung Transplant. 2000;
19(10):984-94.
11. Cassivi SD, Liu M, Boehler A, et al. Transgene expression after
adenovirus-mediated retransfection of rat lungs is increased and pro-
longed by transplant immunosuppression. J Thorac Cardiovasc Surg.
1999;117(1):1-7.
12. Williams RO, Ghrayeb J, Feldmann M, Maini RN. Successful therapy
of collagen-induced arthritis with TNF receptor-IgG fusion protein and
combination with anti-CD4. Immunology. 1995;84(3):433-9.
13. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of
rheumatoid arthritis with a recombinant human tumor necrosis factor
receptor (p75)-Fc fusion protein. N Engl J Med. 1997;337(3):141-7.
14. Le CH, Nicolson AG, Morales A, Sewell KL. Suppression of collagen-
induced arthritis through adenovirus-mediated transfer of a modified
tumor necrosis factor alpha receptor gene. Arthritis Rheum. 1997;
40(9):1662-9.
15. Kim KN, Watanabe S, Ma Y, Thornton S, Giannini EH, Hirsch R.
Viral IL-10 and soluble TNF receptor act synergistically to inhibit
collagen-induced arthritis following adenovirus-mediated gene trans-
fer. J Immunol. 2000;164:1576-81.
16. Ghivizzani SC, Lechman ER, Kang R, et al. Direct adenovirus-medi-
ated gene transfer of interleukin 1 and tumor necrosis factor  soluble
receptors to rabbit knees with experimental arthritis has local and distal
anti-arthritic effects. Proc Natl Acad Sci U S A. 1998;95:4613-8.
17. Zhang H, Zhou T, Yang P, Edwards CK III, Curiel DT, Mountz JD.
Inhibition of tumor necrosis factor  decreases inflammation and
prolongs adenovirus gene expression in lung and liver. Hum Gene
Ther. 1998;9:1875-84.
18. Daddi N, Suda T, D’Ovidio F, et al. Recipient intramuscular cotrans-
fection of naked plasmid TGF1 and IL-10 ameliorates lung graft
ischemia-reperfusion injury. J Thorac Cardiovasc Surg. 2002;124:
259-69.
19. Elkon KB, Liu CC, Gall JG, et al. Tumor necrosis factor  plays a
central role in immune-mediated clearance of adenoviral vectors. Proc
Natl Acad Sci U S A. 1997;94:9814-9.
20. Gall J, Kass-Eisler A, Leinwand L, Falck-Pedersen E. Adenovirus type
5 and 7 capsid chimera: fiber replacement alters receptor tropism
without affecting primary immune neutralization epitopes. J Virol.
1996;70:2116-23.
21. Blau HM, Springer ML. Gene therapy—a novel form of drug delivery.
N Engl J Med. 1995;2:1204-7.
22. Minter RM, Rectenwald JE, Fukuzuka K, et al. TNF receptor sig-
naling and IL-10 gene therapy regulate the innate and humoral immune
responses to recombinant adenovirus in the lung. J Immunol. 2000;
164(1):443-51.
23. Abraham E, Coulson WF, Schwartz MD, Allbee J. Effects of therapy
with soluble tumor necrosis factor receptor fusion protein on pulmo-
nary cytokine expression and lung injury following hemorrhage and
resuscitation. Clin Exp Immunol. 1994;98:29-34.
24. Suga M, Gladdy R, Xing Z, Keshavjee SH, Liu M. Transplant immu-
nosuppression enhances efficiency of adenoviral-mediated gene re-
transfection: inhibition of interferon-gamma and immunoglobulin G.
Ann Thorac Surg. 2002;73:1092-7.
25. Kolb M, Inman M, Margetts PJ, Galt T, Gauldie J. Budesonide
enhances repeated gene transfer and expression in the lung with
adenoviral vectors. Am J Respir Crit Care Med. 2001;164(5):866-72.
26. Beutler B. TNF, immunity and inflammatory disease: lessons of the
past decade. J Investig Med. 1995;43:227-35.
27. Kolls JK, Lei D, Nelson S, Summer WR, Greenberg S, Beutler B.
Adenovirus-mediated blockade of tumor necrosis factor in mice pro-
tects against endotoxic shock yet impairs pulmonary host defense.
J Infect Dis. 1995;171(3):570-5.
Suda et al General Thoracic Surgery
The Journal of Thoracic and Cardiovascular Surgery ● Volume 126, Number 4 1161
G
TS
